Heat biologics, inc. (HTBX)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Revenue:
Grant and licensing revenue

3,049

5,793

-

-

-

-

-

-

Licensing Revenue

-

-

-

-

0

-

-

-

Grant and licensing revenue

-

-

1,519

341

-

-

-

3

Operating expenses:
Research and development

13,013

16,233

8,267

9,330

16,666

2,861

2,737

902

Clinical and regulatory

-

-

-

-

-

5,348

1,397

253

General and administrative

9,431

7,025

6,370

4,138

4,356

3,978

2,429

1,189

Goodwill impairment loss

737

-

-

-

-

-

-

-

Change in fair value of contingent consideration

613

495

224

0

-

-

-

-

Total operating expenses

23,794

23,754

14,862

13,468

21,022

12,187

6,564

2,345

Loss from operations

-20,745

-17,960

-13,342

-13,127

-21,022

-12,187

-6,564

-2,342

Interest income

431

265

22

31

66

-

-

-

Interest income

-

-

-

-

-

73

-

-

Interest income

-

-

-

-

-

-

10

-

Interest income

-

-

-

-

-

-

-

0

Other (expense) income, net

-25

117

101

670

198

-24

23

-7

Interest expense

-

-

-

549

363

41

79

101

Total non-operating income (loss)

406

383

123

152

-99

-56

-45

-108

Net loss before income taxes

-20,339

-17,576

-13,219

-12,974

-

-

-

-

Income tax (expense) benefit

45

-985

-809

0

-

-

-

-

Net loss

-20,384

-16,591

-12,409

-12,974

-21,121

-12,243

-6,609

-

Net loss

-

-

-

-

-

-

-

-2,451

Loss from discontinued operations

-

-

-

-

-

-

-

-20

Net Loss

-

-

-

-

-

-

-

-2,471

Net loss - non-controlling interest

-367

-857

-568

-400

-826

-454

-198

-50

Beneficial conversion charge

-

-

-

-

-

-

-2,300

0

Preferred stock dividend

-

-

-

-

-

-

361

0

Net loss attributable to Heat Biologics, Inc.

-20,017

-15,733

-11,841

-12,573

-20,295

-11,789

-9,073

-2,420

Net loss per share attributable to Heat Biologics, Inc.-basic and diluted

-0.60

-0.90

-3.08

-7.15

-2.53

-1.83

-2.42

-1.32

Weighted-average number of common shares used in net loss per share attributable to Heat Biologics, Inc.-basic and diluted

33,281

17,485

3,845

1,758

8,015

6,454

3,747

1,831

Net loss

-20,384

-16,591

-12,409

-12,974

-21,121

-12,243

-6,609

-

Unrealized gain (loss) on foreign currency translation

8

146

-93

14

-86

0

-

-

Total comprehensive loss

-20,376

-16,445

-12,503

-12,960

-21,208

-12,243

-

-

Comprehensive loss attributable to non-controlling interest

-367

-857

-568

-400

-826

-454

-

-

Comprehensive loss - Heat Biologics, Inc.

-20,008

-15,587

-11,935

-12,559

-20,381

-11,789

-

-